Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: A double-blind, randomized, placebo-controlled crossover trial

Clinical Cardiology

Volumn 36, Issue 8, 2013, Pages 480-485

  Hong, Sung Jin ^a   Chang, Hyuk Jae ^a,b   Park, Sungha ^a   Kang, Dae Ryong ^b   Shin, Sanghoon ^a   Cho, In Jeong ^a   Shim, Chi Young ^a   Hong, Geu Ru ^a   Ha, Jong Won ^a   Chung, Namsik ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ADULT; ARTICLE; AUGMENTATION INDEX; BLOOD VESSEL PARAMETERS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; FEMALE; FIRST DEGREE RELATIVE; HUMAN; MALE; OUTCOME ASSESSMENT; PREMATURE CORONARY ARTERY DISEASE; PRIMARY PREVENTION; PROSPECTIVE STUDY; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; REACTIVE HYPEREMIA INDEX; TREATMENT DURATION;

AGE OF ONSET; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; MALE; MIDDLE AGED; PEDIGREE; PHENOTYPE; PRIMARY PREVENTION; PROSPECTIVE STUDIES; PYRROLES; REPUBLIC OF KOREA; TIME FACTORS; TREATMENT OUTCOME;

EID: 84882243479     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22152     Document Type: Article

References (27)

1. Nasir K, Michos ED, Rumberger JA, et al. Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation. 2004; 110: 2150-2156.
2. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr, et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA. 2004; 291: 2204-2211.
3. Andresdottir MB, Sigurdsson G, Sigvaldason H, et al. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J. 2002; 23: 1655-1663.
4. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2010; 122: e584-e636.
5. Yanek LR, Moy TF, Blumenthal RS, et al. Hypertension among siblings of persons with premature coronary heart disease. Hypertension. 1998; 32: 123-128.
6. Hengstenberg C, Holmer SR, Mayer B, et al. Siblings of myocardial infarction patients are overlooked in primary prevention of cardiovascular disease. Eur Heart J. 2001; 22: 926-933.
7. Joshi PH, Chaudhari S, Blaha MJ, et al. A point-by-point response to recent arguments against the use of statins in primary prevention: this statement is endorsed by the American Society for Preventive Cardiology. Clin Cardiol. 2012; 35: 404-409.
8. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995; 332: 481-487.
9. O'Driscoll G, Green D, Taylor RR,. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 1997; 95: 1126-1131.
10. Dupuis J, Tardif JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999; 99: 3227-3233.
11. Davignon J, Ganz P,. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109 (23 suppl 1): III27-III32.
12. Schachinger V, Britten MB, Zeiher AM,. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation. 2000; 101: 1899-1906.
13. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation. 2002; 106: 653-658.
14. Hunt SC, Williams RR, Barlow GK,. A comparison of positive family history definitions for defining risk of future disease. J Chronic Dis. 1986; 39: 809-821.
15. Bonetti PO, Pumper GM, Higano ST, et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004; 44: 2137-2141.
16. Hamburg NM, Benjamin EJ,. Assessment of endothelial function using digital pulse amplitude tonometry. Trends Cardiovasc Med. 2009; 19: 6-11.
17. Rubinshtein R, Kuvin JT, Soffler M, et al. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. 2010; 31: 1142-1148.
18. Borlaug BA, Olson TP, Lam CS, et al. Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2010; 56: 845-854.
19. Julious SA,. Sample sizes for clinical trials with normal data. Stat Med. 2004; 23: 1921-1986.
20. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-3421.
21. Wang TJ, Nam BH, D'Agostino RB, et al. Carotid intima-media thickness is associated with premature parental coronary heart disease: the Framingham Heart Study. Circulation. 2003; 108: 572-576.
22. Kang MK, Chang HJ, Kim YJ, et al. Prevalence and determinants of coronary artery disease in first-degree relatives of premature coronary artery disease. Coron Artery Dis. 2012; 23: 167-173.
23. Vita JA, Yeung AC, Winniford M, et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation. 2000; 102: 846-851.
24. Mulders TA, Sivapalaratnam S, Stroes ES, et al. Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc Imaging. 2012; 5: 252-260.
25. Wassmann S, Faul A, Hennen B, et al. Rapid effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition on coronary endothelial function. Circ Res. 2003; 93: e98-e103.
26. Tsunekawa T, Hayashi T, Kano H, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme a reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation. 2001; 104: 376-379.
27. Schneider MP, Schmidt BM, John S, et al. Effects of statin treatment on endothelial function, oxidative stress and inflammation in patients with arterial hypertension and normal cholesterol levels. J Hypertens. 2011; 29: 1757-1764.